Analyst Price Target is $27.00
▲ +0.07% Upside Potential
This price target is based on 2 analysts offering 12 month price targets for Myovant Sciences in the last 3 months. The average price target is $27.00, with a high forecast of $27.00 and a low forecast of $27.00. The average price target represents a 0.07% upside from the last price of $26.98.
Current Consensus is
The current consensus among 2 contributing investment analysts is to hold stock in Myovant Sciences. This Hold consensus rating has held steady for over two years.
Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of therapies for the treatment of women's health and endocrine diseases. It offers ORGOVYXTM, an oral gonadotropin-releasing hormone (GnRH) receptor antagonist for the treatment of adult patients with advanced prostate cancer, and MYFEMBREE, which is taken for the management of heavy menstrual bleeding associated with uterine fibroids. The company was founded on February 2, 2016 and is headquartered in London, the United Kingdom.